ACTIVESITE PHARMACEUTICALS, INC.

Basic Information

1456 Fourth St., Unit C
BERKELEY, CA, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 624362419
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Novel Orally-Active Plasma Kallikrein Inhibitors for Diabetic Retinopathy

    Amount: $1,359,943.00

    DESCRIPTION (provided by applicant): There are nearly 24 million people in the U.S. who suffer from diabetes and all are at risk for developing diabetic macular edema (DME), a vision-threatening r ...

    SBIR Phase II 2012 Department of Health and Human Services
  2. Novel Orally-Active Plasma Kallikrein Inhibitors for Diabetic Retinopathy

    Amount: $824,835.00

    DESCRIPTION (provided by applicant): There nearly 24 million people in the U.S. who suffer from diabetes and who are at risk for diabetic retinopathy (DR), a vascular complication of diabetes that is ...

    SBIR Phase II 2009 Department of Health and Human Services
  3. Novel Anti-Thrombotic Approach for Treatment of Myocardial Infarction

    Amount: $224,868.00

    DESCRIPTION (provided by applicant): More than 850,000 myocardial infarctions (MI) occur in the US annually, 300,000 of which are recurrences, carrying with them a two-fold increased risk of death. Re ...

    SBIR Phase I 2007 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government